Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Monotherapy
ZL-1201 · 1 trial · 1 indication
Incidence of Treatment-Emergent Adverse Events as Assessed by CTCAE v5.0
| Arm | Type | Description |
|---|---|---|
| Single arm, ZL-1201 | EXPERIMENTAL | Single arm, ZL-1201 |
| Name | Type | Description |
|---|---|---|
| ZL-1201 | DRUG | Part 1 \& 2: Escalating dose of ZL-1201, Part 3: three dose levels determined from Part 1 and Part 2. |
Inclusion Criteria: * Histologically/cytologically confirmed, locally advanced unresectable or metastatic solid tumors and lymphomas that are refractory or intolerant to standard of care therapy, or for which no standard therapy exists. * Adequate hematologic status * Adequate coagulation function ...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
ZL-1201 is an investigational small molecule developed by Zai Lab Limited for the treatment of advanced cancer. It is a CD47-targeted therapy that has been studied in a Phase 1 clinical trial. ZL-1201 is not approved and remains in clinical development.
ZL-1201 targets CD47, a protein that cancer cells use to evade immune detection. By binding CD47, ZL-1201 is designed to enable immune cells such as macrophages to recognize and attack tumor cells. CD47 is a protein target, and ZL-1201 is a small molecule therapeutic.
ZL-1201 is developed by Zai Lab Limited, a biopharmaceutical company traded on the Nasdaq under the ticker ZLAB. Zai Lab is advancing ZL-1201 as part of its oncology pipeline for patients with advanced cancer.
ZL-1201 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The Phase 1 program has been conducted in patients with advanced cancer.
ZL-1201 has been evaluated in one Phase 1 clinical trial, NCT04257617, titled A Trial of ZL-1201 in Subjects With Advanced Cancer. The trial enrolled 37 participants across the United States and China, was uncontrolled, and has been completed.